IP Library Granted Patent US 7,157,238
Granted Patent B2
US 7,157,238 · App. 09/926,323 · Granted Jan 2, 2007

Diagnostic and therapeutic use of antibodies against the urokinase receptor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,157,238
App. No.
09/926,323
Granted
Jan 2, 2007
Kind
B2
Abstract

The invention concerns a method and a reagent kit for detecting cells in a biological sample using a double-fluorescence technique and the diagnostic and therapeutic application of amino acid sequence-specific antibodies against the urokinase receptor having a high affinity for tumour cell-expressed receptors.

Claims (14)

1. A method for determining the prognosis of the course of a malignant disease, comprising

obtaining a sample from a subject suspected of containing tumor cells,

contacting said sample with an antibody or an antigen-binding fragment thereof, which binds to the epitope 52–60 of the human urokinase receptor (uPAR), wherein a binding of the antibody or the antigen-binding fragment thereof with tumor cells in the sample is indicative of a tumor and gives a prognosis for the course of a malignant disease in said subject.

2. The method according to claim 1 , wherein said tumor cells are disseminated tumor cells in bone marrow.

3. The method according to claim 1 , wherein said sample is contacted with said antibody or an antigen-binding fragment in an ELISA.

4. The method according to claim 1 , wherein said binding of the antibody or the antigen-binding fragment thereof with tumor cells is determined in a double-fluorescence detection method.

5. The method according to claim 1 , wherein said antibody is the monoclonal antibody IIIF10, or antigen binding fragments thereof has the same binding specificity as monoclonal antibody IIIF10, or an antibody or antibody fragment having a binding specificity to the epitope 52–60 of uPAR.

6. The method according to claim 5 , wherein said antibody comprises

(a) a CDR3-VH amino acid sequence (I) D G S M G G F D Y (SEQ ID NO:5), and

(b) a CDR3-VL amino acid sequence (II) L Q H W N Y P Y T (SEQ ID NO:6),

(c) a CDR1-VH amino acid sequence S Y D I N (SEQ ID NO:7),

(d) a CDR1-VL amino acid sequence K A S Q N V R T T V A (SEQ ID NO: 8),

(e) a CDR2-VH amino acid sequence W I F P G D G S T N Y N E K F K D (SEQ ID NO: 9), and

(f) a CDR2-VL amino acid sequence L A S N R H T (SEQ ID NO: 10).

Assignments (3)
RE-RECORD TO CORRECT PROPERTY NUMBER ON A DOCUMENT PREVIOUSLY RECORDED AT REEL 022127, FRAME 0451. (ASSIGNMENT OF ASSIGNOR'S INTEREST) Recorded Apr 20, 2009
From: WILEX AG
To: WILEX AG
Reel/Frame 022575/0312 →
CHANGE OF ADDRESS WITH TRANSLATION Recorded Jan 16, 2009
From: WILEX AG
To: WILEX AG
Reel/Frame 022127/0451 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2002
From: SCHMITT, MANFRED; NOACK, FRANK; MAGDOLEN, VIKTOR; GRAEFF, HENNER; LUTHER, THOMAS; ALBRECHT, SYBILLE; MULLER, MARTIN; WILHELM, OLAF; HARBECK, NADIA
To: WILEX AG
Reel/Frame 012882/0931 →